Alkermes
Alkermes plc, a leading biopharmaceutical company headquartered in Ireland, focuses on developing innovative therapies for central nervous system (CNS) disorders and addiction. Founded in 1987, Alkermes has established a strong presence in the global healthcare market, with significant operations in the United States and Europe. The company is renowned for its unique drug delivery technologies and a robust portfolio of products, including treatments for schizophrenia, depression, and opioid dependence. Alkermes' commitment to addressing complex medical needs has positioned it as a key player in the biopharmaceutical industry, with notable achievements in advancing patient care through its proprietary formulations. With a focus on scientific excellence and patient-centric solutions, Alkermes continues to drive innovation and improve outcomes for individuals affected by serious mental health conditions.
DitchCarbon Score
How does Alkermes's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkermes's score of 22 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alkermes's reported carbon emissions
In 2023, Alkermes reported greenhouse gas emissions of approximately 250 kg CO2e per employee and 50 kg CO2e per square metre of floor area, reflecting their Scope 1 and 2 emissions. The company has not disclosed specific total emissions figures or Scope 3 emissions data for this year. In 2022, the emissions per square metre for combined Scope 1 and 2 GHG emissions were about 27 kg CO2e, while in 2021, this figure was approximately 7 kg CO2e per square metre. Additionally, the GHG emissions per million dollars of revenue were reported at about 0.0000015 kg CO2e in 2023 and 0.000003 kg CO2e in 2021. Despite the absence of formal reduction targets or commitments to the Science Based Targets initiative (SBTi), Alkermes is actively monitoring its emissions and has established metrics to assess its environmental impact. The company continues to focus on improving its sustainability practices, although specific reduction initiatives have not been detailed.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alkermes is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
